Selskabets formål er at drive virksomhed med udvikling, produktion og salg af in vitro diagnostika til mikrobiologisk diagnostik og kontrol samt hygiejnemonitorering i indland og udland, samt anden dermed beslægtet virksomhed.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 320.2 mio. | -107.4 mio. | 3 mia. | 695.8 mio. | 136 | |
CVR: 37294535
Secondary names: SSI Diagnostica Group A/S
1 properties
Upgrade to Pro to see addresses, building data and ownership details
Compared to 131 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Joseph Edward Bernardo joined the board
Stig Løkke Pedersen left the board
Egil Mølsted Madsen left the board
The financial health of SSI Diagnostica A/S shows significant volatility, with a concerning trend of increasing losses over the past three years. In 2025, the company reported revenue of 320.25 million DKK but incurred a substantial loss of 107.42 million DKK, following a loss of 57.74 million DKK in 2024. Despite these challenges, equity remains relatively strong at 695.79 million DKK, although it has declined from 1.27 billion DKK in 2024. The fluctuating revenue and profitability indicate potential operational inefficiencies or market challenges, positioning the company as a player in the pharmaceutical manufacturing industry that may need to address its profitability and operational strategies moving forward.
AI-generated summary
Companies in the same industry and area
companydata.dk